Cohort characteristics
| Variable . | All patients (N = 815) . | Female patients (n = 469) . | Male patients (n = 346) . | P . |
|---|---|---|---|---|
| Age at diagnosis, mean ± SD, y | 51.28 ± 16.26 | 49.6 ± 16.56 | 53.55 ± 15.58 | .001 |
| Race | ||||
| White | 689 (84.5) | 386 (82.3) | 303 (87.6) | .040 |
| African American | 85 (10.4) | 60 (12.8) | 25 (7.2) | .010 |
| Hispanic | 5 (0.6) | 3 (0.6) | 2 (0.6) | 1.000 |
| Asian | 36 (4.4) | 20 (4.3) | 16 (4.6) | .864 |
| Phenotype at diagnosis | ||||
| ET | 381 (46.7) | 252 (53.7) | 129 (37.3) | <.001 |
| PV | 289 (35.5) | 163 (34.8) | 126 (36.4) | .656 |
| PMF | 145 (17.8) | 54 (11.5) | 91 (26.3) | <.001 |
| MPN-specific mutation | ||||
| JAK2+ | 606 (74.4) | 343 (73.1) | 263 (76) | .372 |
| JAK2– | 209 (25.6) | 126 (26.9) | 83 (24) | .372 |
| CALR+ | 129 (15.8) | 68 (14.5) | 61 (17.6) | .442 |
| MPL+ | 21 (2.6) | 15 (3.2) | 6 (1.7) | .179 |
| Triple-negative | 45 (5.5) | 35 (7.5) | 10 (2.9) | .005 |
| JAK2– others not done | 14 (1.7) | 8 (1.7) | 6 (1.7) | .957 |
| Karyotype (n = 389) | ||||
| Normal | 226 (58.1) | 125 (62.2) | 101 (53.7) | .100 |
| 1 lesion | 81 (20.8) | 36 (17.9) | 45 (23.9) | .169 |
| ≥2 lesions | 82 (21.1) | 40 (19.9) | 42 (22.3) | .619 |
| Treatments | ||||
| None | 388 (47.6) | 230 (49) | 158 (45.7) | .356 |
| Hydroxyurea | 293 (36) | 150 (32) | 143 (41.3) | .006 |
| Anagrelide | 74 (9.1) | 53 (11.3) | 21 (6.1) | .013 |
| Interferon | 82 (10.1) | 56 (11.9) | 26 (7.5) | .045 |
| Ruxolitinib | 122 (15) | 54 (11.5) | 67 (19.4) | .002 |
| Allogeneic stem cell transplantation | 39 (4.8) | 13 (2.8) | 26 (7.5) | .002 |
| Enrolled within 1 y from diagnosis | 229 (28) | 116 (24.7) | 113 (32.7) | .015 |
| Variable . | All patients (N = 815) . | Female patients (n = 469) . | Male patients (n = 346) . | P . |
|---|---|---|---|---|
| Age at diagnosis, mean ± SD, y | 51.28 ± 16.26 | 49.6 ± 16.56 | 53.55 ± 15.58 | .001 |
| Race | ||||
| White | 689 (84.5) | 386 (82.3) | 303 (87.6) | .040 |
| African American | 85 (10.4) | 60 (12.8) | 25 (7.2) | .010 |
| Hispanic | 5 (0.6) | 3 (0.6) | 2 (0.6) | 1.000 |
| Asian | 36 (4.4) | 20 (4.3) | 16 (4.6) | .864 |
| Phenotype at diagnosis | ||||
| ET | 381 (46.7) | 252 (53.7) | 129 (37.3) | <.001 |
| PV | 289 (35.5) | 163 (34.8) | 126 (36.4) | .656 |
| PMF | 145 (17.8) | 54 (11.5) | 91 (26.3) | <.001 |
| MPN-specific mutation | ||||
| JAK2+ | 606 (74.4) | 343 (73.1) | 263 (76) | .372 |
| JAK2– | 209 (25.6) | 126 (26.9) | 83 (24) | .372 |
| CALR+ | 129 (15.8) | 68 (14.5) | 61 (17.6) | .442 |
| MPL+ | 21 (2.6) | 15 (3.2) | 6 (1.7) | .179 |
| Triple-negative | 45 (5.5) | 35 (7.5) | 10 (2.9) | .005 |
| JAK2– others not done | 14 (1.7) | 8 (1.7) | 6 (1.7) | .957 |
| Karyotype (n = 389) | ||||
| Normal | 226 (58.1) | 125 (62.2) | 101 (53.7) | .100 |
| 1 lesion | 81 (20.8) | 36 (17.9) | 45 (23.9) | .169 |
| ≥2 lesions | 82 (21.1) | 40 (19.9) | 42 (22.3) | .619 |
| Treatments | ||||
| None | 388 (47.6) | 230 (49) | 158 (45.7) | .356 |
| Hydroxyurea | 293 (36) | 150 (32) | 143 (41.3) | .006 |
| Anagrelide | 74 (9.1) | 53 (11.3) | 21 (6.1) | .013 |
| Interferon | 82 (10.1) | 56 (11.9) | 26 (7.5) | .045 |
| Ruxolitinib | 122 (15) | 54 (11.5) | 67 (19.4) | .002 |
| Allogeneic stem cell transplantation | 39 (4.8) | 13 (2.8) | 26 (7.5) | .002 |
| Enrolled within 1 y from diagnosis | 229 (28) | 116 (24.7) | 113 (32.7) | .015 |
Data are expressed as n (%) unless otherwise indicated.